Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

22.98 +0.15 (+0.64%)
Streaming Delayed Price Updated: 12:58 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
Exposures COVID-19 Product Safety
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions... 
Via Benzinga
Exposures COVID-19 Product Safety
India Market Watch: Muted Start For Nifty, Sensex — Defense Stocks, Delhivery Shine
Via Stocktwits
1 Profitable Stock on Our Watchlist and 2 to Turn Down
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Novavax Wins FDA Approval For COVID-19 Vaccine: Retail Calls For Buyback And Bigger Moves
The pharma company secured FDA clearance to manufacture and distribute its COVID-19 vaccine Nuvaxovid for adults and at-risk groups, with no advisory committee hurdles. 
Via Stocktwits
Exposures COVID-19 Product Safety
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Here are three dividend-paying stocks that warrant closer examination. 
Via The Motley Fool
Exposures COVID-19
Analyst Ethan Billings shares insights on tech stocks
Via Binary News Network
Topics Artificial Intelligence Initial Public Offering
Exposures Artificial Intelligence Securities Market
Here's How Many Shares of Pfizer You Should Own to Make $10,000 in Annual Dividend Income
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
3 Profitable Stocks to Research Further
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline. 
Via StockStory
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Via The Motley Fool
Topics Economy Government
Exposures Interest Rates Political
3 Magnificent S&P 500 Dividend Stocks Down 62%, 63%, and 64% to Buy and Hold Forever
Temporary turbulence has resulted in opportunity for patient, bargain-hunting investors. 
Via The Motley Fool
Topics Economy Stocks World Trade
Exposures Economy Tariff US Equities
Curious about the most active S&P500 stocks in today's session?
Looking for the most active stocks in the S&P500 index on Wednesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market. 
Via Chartmill
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
3 Value Stocks Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock
Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money." 
Via Benzinga
PFE Q1 Earnings Call: Revenue Misses, Margin Expansion, and Focus on Pipeline Productivity
Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 7.8% year on year to $13.72 billion. The company’s full-year revenue guidance... 
Via StockStory
Topics World Trade
Exposures Tariff
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative. 
Via Chartmill
Topics Government World Trade
Exposures Political Tariff
Which S&P500 stocks are the most active on Monday?
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
Ford’s Cologne Workers To Strike On Wednesday, Says Report: Retail Sentiment Sours
According to a Reuters report, the strike comes in the wake of planned job cuts in the region. 
Via Stocktwits
Topics Government
Exposures Political
KindlyMD Stock Surges To All-Time High After Announcing Merger With Nakamoto To Launch Bitcoin Treasury Strategy
KindlyMD CEO Tim Pickett said the merger allows the company to preserve and expand its mission to combat opioid dependency through alternative medicine while gaining a new engine for shareholder value... 
Via Stocktwits
Topics Government Regulatory Compliance
Exposures Legal Political Regulatory
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order
The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries. 
Via Stocktwits
Topics Government
Exposures Political
Top S&P500 movers in Monday's pre-market session
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company...Ask Your PBM For A List Of Claims'
Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main... 
Via Benzinga
Wondering if Pfizer's 7.6% Dividend Yield Is Sustainable? Here's What You Need to Know.
Via The Motley Fool
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
Exposures Political
Trump's Drug Price Slash Plan Sparks Retail Buzz As Investors Eye Big Pharma Fallout
The proposal, citing a "Most Favored Nation Policy," fueled debate prompted some watchers to question the legality and feasibility of the move, while others speculated on its potential market impact. 
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%. 
Via Benzinga
Topics Government
Exposures Political
3 Magnificent S&P 500 Dividend Stocks Down 30% to Buy and Hold Forever
These household names and index components are yielding better than 4.5% with compelling valuations. 
Via The Motley Fool
Topics Stocks World Trade
Exposures Tariff US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.